Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.

Also called NCT01195246

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 155 participants (enrolled count) (from the registry)
Sponsor
Dynavax Technologies Corporation (from the registry)
Registry
  • NCT NCT01195246
  • EudraCT 2010-019633-10
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01195246. Randomized; triple masking; primary purpose prevention. Start 2010-12 (registry gives no type); primary completion 2012-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
Condition
End Stage Renal Disease
Intervention (Biological)
HEPLISAV
Intervention (Biological)
Engerix-B
Intervention (Biological)
Fendrix
Lead sponsor
Dynavax Technologies Corporation (class: industry)

Record details

Record id
cardio:ct-nct01195246
Content hash
14970a2b865bf0dafe0f6ded1a308ecbd191e04989299366d24a9d855e07f13a